Nectar Lifesciences Limited

NSE NECLIFE.NS

Nectar Lifesciences Limited Operating Income for the year ending March 31, 2024: USD 46.64 M

Nectar Lifesciences Limited Operating Income is USD 46.64 M for the year ending March 31, 2024, a 7,510.93% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
  • Nectar Lifesciences Limited Operating Income for the year ending March 31, 2023 was USD -629.40 K, a -104.70% change year over year.
  • Nectar Lifesciences Limited Operating Income for the year ending March 31, 2022 was USD 13.38 M, a 95.98% change year over year.
  • Nectar Lifesciences Limited Operating Income for the year ending March 31, 2021 was USD 6.83 M, a -67.71% change year over year.
  • Nectar Lifesciences Limited Operating Income for the year ending March 31, 2020 was USD 21.14 M, a -26.98% change year over year.
Key data
Date Operating Income EBIT EBITDA Net Income
Market news
Loading...
SV Wall Street
NSE: NECLIFE.NS

Nectar Lifesciences Limited

CEO Mr. Amit Chadah
IPO Date July 18, 2005
Location India
Headquarters SCO 38-39
Employees 1,686
Sector Health Care
Industries
Description

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.

Similar companies

KOPRAN.NS

Kopran Limited

USD 2.10

-2.71%

MOREPENLAB.NS

Morepen Laboratories Limited

USD 0.75

4.08%

SUVEN.NS

Suven Life Sciences Limited

USD 1.48

10.54%

MARKSANS.NS

Marksans Pharma Limited

USD 2.78

0.16%

StockViz Staff

February 1, 2025

Any question? Send us an email